Cas:885266-98-8 4-Bromo-2-chloro-6-(trifluoromethoxy)aniline manufacturer & supplier

Chemical Name:4-Bromo-2-chloro-6-(trifluoromethoxy)aniline

CAS.NO:885266-98-8

Synonyms:4-bromo-2-chloro-6-(trifluoromethoxy)aniline

Molecular Formula:C₇H₄BrClF₃NO

Molecular Weight:290.46500

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:35.25000

Exact Mass:288.91200

LogP:4.16450

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-bromo-2-chloro-6-(trifluoromethoxy)aniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-bromo-2-chloro-6-(trifluoromethoxy)aniline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-bromo-2-chloro-6-(trifluoromethoxy)aniline Use and application,4-bromo-2-chloro-6-(trifluoromethoxy)aniline technical grade,usp/ep/jp grade.

Related News: The upstream of pharmaceutical intermediates is the basic chemical raw material industry. Basic chemical raw materials are bulk commodities and prices fluctuate greatly, which directly affects the production costs of enterprises. 4-Bromo-2-chloro-6-(trifluoromethoxy)aniline manufacturer I believe they came to the right decision on behalf of the American public, Sandrock said in an interview. 4-Bromo-2-chloro-6-(trifluoromethoxy)aniline supplier The results of analysis perfectly align with the tau hypothesis — simply put, if the patient is tau biomarker positive, then tau pathology is responsible for his/her cognitive decline, and halting tau pathology should slow or halt progression,” Novak said. “If the patient is negative for markers of tau pathology, then this patient’s impairment is mainly due to other pathologies, and treating tau pathology in this patient won’t be meaningful. 4-Bromo-2-chloro-6-(trifluoromethoxy)aniline vendor The acquired pharmaceutical intermediates business will be renamed Corden Pharma Switzerland LLC and will operate as part of ICIG��s pharmaceutical business within the Corden Pharma platform. The companies�� goal is to close the transaction during the first quarter of 2011. Financial terms are not disclosed. 4-Bromo-2-chloro-6-(trifluoromethoxy)aniline factory Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.